{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:28:53Z","timestamp":1787236133223,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.01.751","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:51:29Z","timestamp":1770133889000},"page":"861-867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Denosumab Therapy Beyond 10 Years: Subsequent Treatment and Densitometric Outcomes"],"prefix":"10.1016","volume":"32","author":[{"given":"Xi","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly H.","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie H.N.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol H.Y.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.B.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Cho","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-1126","authenticated-orcid":false,"given":"David T.W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.01.751_bib1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.01.751_bib2","first-page":"1","article-title":"2024 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong","volume":"30","author":"Ip","year":"2024","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.eprac.2026.01.751_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2012.04.006","article-title":"Pathophysiology of osteoporosis: new mechanistic insights","volume":"41","author":"Armas","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.eprac.2026.01.751_bib4","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3803\/EnM.2021.301","article-title":"Long-term treatment of postmenopausal osteoporosis","volume":"36","author":"Brown","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.eprac.2026.01.751_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2026.01.751_bib6","article-title":"Strategies for denosumab discontinuation in postmenopausal osteoporosis","volume":"93","author":"Degbo\u00e9","year":"2025","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.eprac.2026.01.751_bib7","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.01.751_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3803\/EnM.2024.2125","article-title":"Long-term efficacy and safety of denosumab: insights beyond 10 years of use","volume":"40","author":"Ha","year":"2025","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.eprac.2026.01.751_bib9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3803\/EnM.2024.2262","article-title":"Osteoporosis management after the occurrence of medication-related osteonecrosis of the jaw: a 13-Year experience at a tertiary center","volume":"40","author":"Wong","year":"2025","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.eprac.2026.01.751_bib22","series-title":"Applied longitudinal analysis","author":"Fitzmaurice","year":"2012"},{"key":"10.1016\/j.eprac.2026.01.751_bib10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C-Based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.01.751_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2026.01.751_bib12","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch Study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.01.751_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.01.751_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00774-025-01590-2","article-title":"Sequential and combination therapy with romosozumab","volume":"43","author":"Kobayakawa","year":"2025","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.eprac.2026.01.751_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-025-00909-2","article-title":"Sequential and long-term therapy for osteoporosis","volume":"23","author":"McClung","year":"2025","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.eprac.2026.01.751_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.01.751_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.11005\/jbm.2024.31.3.246","article-title":"Denosumab in osteoporosis: predicting long-term efficacy beyond 10 years","volume":"31","author":"Lee","year":"2024","journal-title":"J Bone Metab"},{"key":"10.1016\/j.eprac.2026.01.751_bib18","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jbmr\/zjaf037","article-title":"Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures","volume":"40","author":"Kumar","year":"2025","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2026.01.751_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","article-title":"Clinical experience with denosumab discontinuation","volume":"36","author":"Laursen","year":"2025","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2026.01.751_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00774-023-01477-0","article-title":"Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study","volume":"42","author":"Miyauchi","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.eprac.2026.01.751_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Jt Bone Spine"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:27:35Z","timestamp":1781018855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26007755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1530891X26007755"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.751","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab Therapy Beyond 10 Years: Subsequent Treatment and Densitometric Outcomes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}